Skip to content

Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients

Hyperspectral Endoscopy Imaging for Early Detection of Precancerous Lesions in Average Risk Patients: Proof of Principle

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04172493
Enrollment
13
Registered
2019-11-21
Start date
2019-08-26
Completion date
2020-01-27
Last updated
2020-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient

Brief summary

This trial studies whether hyperspectral endoscopy improves visualization of abnormal tissue in average risk patients during standard-of-care colonoscopies. Hyperspectral endoscopy is an emerging technique that has the potential to enable the signals from blood to be resolved from tissue-specific signals. Image-enhanced endoscopy may improve visualization of abnormal colonic tissue when compared to the standard-of-care high-definition white light endoscopy.

Detailed description

PRIMARY OBJECTIVE: I. To assess whether use of hyperspectral endoscopy (HySE) can improve visualization of abnormal colonic tissue. SECONDARY OBJECTIVES: I. To assess whether use of HySE could reduce the rate of missed flat polyps. II. To assess whether use of HySE might in the future reduce the incomplete resection rate (IRR). III. To examine accuracy of practitioners in predicting polyp histology. OUTLINE: Patients undergo standard of care white light endoscopy and hyperspectral endoscopy during routine colonoscopy procedure. After completion of study, patients who experience a colonoscopy-related severe adverse event are followed up until resolution or stabilization of the event.

Interventions

PROCEDUREHyperspectral Endoscopy (HySE)

Undergo hyperspectral endoscopy

Undergo white light endoscopy

Sponsors

National Cancer Institute (NCI)
CollaboratorNIH
Oregon Health and Science University
CollaboratorOTHER
OHSU Knight Cancer Institute
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DEVICE_FEASIBILITY
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Ability to understand and the willingness to sign a written informed consent document * Patients scheduled for a standard of care screening or surveillance colonoscopy

Exclusion criteria

* Any condition that, in the opinion of the investigator, precludes the patient from completion of the study procedure

Design outcomes

Primary

MeasureTime frameDescription
Spectral profiles corresponding to normal versus abnormal colonic tissue1 yearWill apply a multivariate statistical analysis such as spectral angle mapper to determine whether the spectra are significantly different as determined by light spectral bandwidth measurements.
Image quality1 yearAssessed by the endoscopist, based on level of confidence in delineating the area of interest. Will assess and compare the number of polyps found by standard light endoscopy and narrow band imaging with hyperspectral endoscopy.

Secondary

MeasureTime frameDescription
Imaging differences in polyp characteristics documented upon post-procedure video review1 yearWill be compared with the final read of the pathology of the polyps. A Pearson X2 test or equivalent test will be applied. When applicable, Fisher exact test and Pearson X2 test will be used to test for differences in categorical variables, which include analysis of polyp morphologic structure and location. A student t test or equivalent statistical test will be used to test for differences in continuous variables, including polyp diameter.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026